Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of antiretroviral compounds with potent activity against HIV-1 replication. Several are in late stages of clinical development. The antiviral potency, rapid onset of action, and lack of toxicity of NNRTIs will likely make them a useful addition for the practicing clinician treating HIV-infected patients. However, rapid development of viral resistance to NNRTIs will limit the utility of these compounds in monotherapy. Used in combination with other antiretroviral agents, NNRTIs have shown promising results in clinical trials by decreasing viral burden and promoting sustained increases in CD4+T-cell counts. This should lead to an increase in the quality and longevity of life for HIV-infected individuals.

Original languageEnglish (US)
Pages (from-to)715-731
Number of pages17
JournalInfections in Medicine
Volume13
Issue number8
StatePublished - Dec 1 1996

Fingerprint

Reverse Transcriptase Inhibitors
HIV
Anti-Retroviral Agents
CD4 Lymphocyte Count
Viral Load
Antiviral Agents
HIV-1
Quality of Life
Clinical Trials
T-Lymphocytes

Keywords

  • Acquired immune deficiency syndrome (AIDS)
  • Delavirdine
  • Human immunodeficiency virus (HIV)
  • Nevirapine
  • Non-nucleoside reverse transcriptase inhibitors

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

The new non-nucleoside reverse transcriptase inhibitors. / Swindells, Susan; Gendelman, Howard Eliot.

In: Infections in Medicine, Vol. 13, No. 8, 01.12.1996, p. 715-731.

Research output: Contribution to journalArticle

@article{84858a89d8794200b33e3da37a569611,
title = "The new non-nucleoside reverse transcriptase inhibitors",
abstract = "Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of antiretroviral compounds with potent activity against HIV-1 replication. Several are in late stages of clinical development. The antiviral potency, rapid onset of action, and lack of toxicity of NNRTIs will likely make them a useful addition for the practicing clinician treating HIV-infected patients. However, rapid development of viral resistance to NNRTIs will limit the utility of these compounds in monotherapy. Used in combination with other antiretroviral agents, NNRTIs have shown promising results in clinical trials by decreasing viral burden and promoting sustained increases in CD4+T-cell counts. This should lead to an increase in the quality and longevity of life for HIV-infected individuals.",
keywords = "Acquired immune deficiency syndrome (AIDS), Delavirdine, Human immunodeficiency virus (HIV), Nevirapine, Non-nucleoside reverse transcriptase inhibitors",
author = "Susan Swindells and Gendelman, {Howard Eliot}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "13",
pages = "715--731",
journal = "Infections in Medicine",
issn = "0749-6524",
publisher = "CMP Healthcare Media LLC",
number = "8",

}

TY - JOUR

T1 - The new non-nucleoside reverse transcriptase inhibitors

AU - Swindells, Susan

AU - Gendelman, Howard Eliot

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of antiretroviral compounds with potent activity against HIV-1 replication. Several are in late stages of clinical development. The antiviral potency, rapid onset of action, and lack of toxicity of NNRTIs will likely make them a useful addition for the practicing clinician treating HIV-infected patients. However, rapid development of viral resistance to NNRTIs will limit the utility of these compounds in monotherapy. Used in combination with other antiretroviral agents, NNRTIs have shown promising results in clinical trials by decreasing viral burden and promoting sustained increases in CD4+T-cell counts. This should lead to an increase in the quality and longevity of life for HIV-infected individuals.

AB - Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of antiretroviral compounds with potent activity against HIV-1 replication. Several are in late stages of clinical development. The antiviral potency, rapid onset of action, and lack of toxicity of NNRTIs will likely make them a useful addition for the practicing clinician treating HIV-infected patients. However, rapid development of viral resistance to NNRTIs will limit the utility of these compounds in monotherapy. Used in combination with other antiretroviral agents, NNRTIs have shown promising results in clinical trials by decreasing viral burden and promoting sustained increases in CD4+T-cell counts. This should lead to an increase in the quality and longevity of life for HIV-infected individuals.

KW - Acquired immune deficiency syndrome (AIDS)

KW - Delavirdine

KW - Human immunodeficiency virus (HIV)

KW - Nevirapine

KW - Non-nucleoside reverse transcriptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0029794412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029794412&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 715

EP - 731

JO - Infections in Medicine

JF - Infections in Medicine

SN - 0749-6524

IS - 8

ER -